trial

Treatment of Acute Schizophrenia With Vitamin Therapy

NCTId NCT00140166
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 55 (estimated)
Sponsored by Beersheva Mental Health Center
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
55 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2005-07
Primary completion
—
Eligibility
ALL · 18 Years · 30 Years

Interventions & indications

Drugs
niacinamidePyridoxineascorbate

Sponsors

Beersheva Mental Health CenterLead Sponsor
Supported by a Hilton Family Foundation grant toCollaborator
International Schizophrenia FoundationCollaborator

Investigators

2
Prof. Vladimir Lerner, MD, PhDPrincipal Investigator
RH Belmaker, MDStudy Director

Sites

1 total
Beersheva, Israel

Facts & assertions

3 sourced
Enrollment
55
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
niacinamide
drug
Pyridoxine
drug
ascorbate
drug
lead_sponsor
Beersheva Mental Health Center
company
collaborator
Supported by a Hilton Family Foundation grant to
company
International Schizophrenia Foundation
company
indication
Schizophrenia
indication
Acute Schizophrenia
indication
investigator
Prof. Vladimir Lerner, MD, PhD
person
RH Belmaker, MD
person